Alzheimer's, Dementia, Parkinson's Disease

Main Content

CREAD II

Study title

Phase 3 multicenter, randomized, double blind, placebo controlled, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer’s disease 

  • Principal Investigator: Juebin Huang, MD PhD

Purpose

This study is to determine if an experimental drug is effective in reducing the amount of amyloid plaque present in patients with mild Alzheimer’s disease.

Who can participate

Those eligible to participate in this study include:

  • Individuals ages of 50-85 with mild Alzheimer’s Disease who test positive for Amyloid Plaque

For more information

  • Andrew Majeste, RN BSN
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 984-5490
  • IRB Number: 2017-0263